These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 30947275)

  • 1. Refractoriness to transarterial chemoembolization in patients with recurrent hepatocellular carcinoma after curative resection.
    Jeon MY; Kim HS; Lim TS; Han DH; Kim BK; Park JY; Kim DY; Ahn SH; Choi GH; Choi JS; Han KH; Kim SU
    PLoS One; 2019; 14(4):e0214613. PubMed ID: 30947275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transarterial chemoembolization versus surgery/radiofrequency ablation for recurrent hepatocellular carcinoma with or without microvascular invasion.
    Jin YJ; Lee JW; Lee OH; Chung HJ; Kim YS; Lee JI; Cho SG; Jeon YS; Lee KY; Ahn SI; Shin WY
    J Gastroenterol Hepatol; 2014 May; 29(5):1056-64. PubMed ID: 24372785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study.
    Ren Y; Cao Y; Ma H; Kan X; Zhou C; Liu J; Shi Q; Feng G; Xiong B; Zheng C
    BMC Cancer; 2019 Oct; 19(1):983. PubMed ID: 31640620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment choice for early-stage hepatocellular carcinoma in real-world practice: impact of treatment stage migration to transarterial chemoembolization and treatment response on survival.
    Roberts SK; Gazzola A; Lubel J; Gow P; Bell S; Nicoll A; Dev A; Fink MA; Sood S; Knight V; Hong T; Paul E; Mishra G; Majeed A; Kemp W;
    Scand J Gastroenterol; 2018; 53(10-11):1368-1375. PubMed ID: 30394145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Combined Radiofrequency Ablation with Transarterial Chemoembolization in Patients with Barcelona Clinic Liver Cancer Stage A Hepatocellular Carcinoma Ineligible for Curative Treatment.
    Kim AR; Park E; Kwon SY; Park SJ; Kim YJ; Yoo BC; Choe WH; Kim JH; Hwang JH; Park SW; Kim YJ; Park HS; Yu MH; Jeon HJ
    Korean J Gastroenterol; 2019 Mar; 73(3):167-176. PubMed ID: 31013560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time to Transcatheter Arterial Chemoembolization Refractoriness in Patients with Hepatocellular Carcinoma in Kinki Criteria Stages B1 and B2.
    Arizumi T; Minami T; Chishina H; Kono M; Takita M; Yada N; Hagiwara S; Minami Y; Ida H; Ueshima K; Kamata K; Minaga K; Komeda Y; Takenaka M; Sakurai T; Watanabe T; Nishida N; Kudo M
    Dig Dis; 2017; 35(6):589-597. PubMed ID: 29040992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transarterial Chemoembolization versus Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma after Resection within Barcelona Clinic Liver Cancer Stage 0/A: A Retrospective Comparative Study.
    Chen R; Gan Y; Ge N; Chen Y; Wang Y; Zhang B; Wang Y; Ye S; Ren Z
    J Vasc Interv Radiol; 2016 Dec; 27(12):1829-1836. PubMed ID: 27553917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transarterial chemoembolization versus hepatic resection in hepatocellular carcinoma treatment: a meta-analysis.
    Tian X; Dai Y; Wang DQ; Zhang L; Sui CG; Meng FD; Jiang SY; Liu YP; Jiang YH
    Drug Des Devel Ther; 2015; 9():4431-40. PubMed ID: 26309396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma.
    Lee IC; Hung YW; Liu CA; Lee RC; Su CW; Huo TI; Li CP; Chao Y; Lin HC; Hou MC; Huang YH
    Liver Int; 2019 Sep; 39(9):1704-1712. PubMed ID: 31319016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transarterial Chemoembolization in Treatment-Naïve and Recurrent Hepatocellular Carcinoma: A Propensity-Matched Outcome Analysis.
    Kim DS; Lim TS; Jeon MY; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Baatarkhuu O; Kim SU
    Dig Dis Sci; 2019 Dec; 64(12):3660-3668. PubMed ID: 31187326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
    Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
    Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma.
    Pecorelli A; Lenzi B; Gramenzi A; Garuti F; Farinati F; Giannini EG; Ciccarese F; Piscaglia F; Rapaccini GL; Di Marco M; Caturelli E; Zoli M; Borzio F; Sacco R; Cabibbo G; Felder M; Morisco F; Gasbarrini A; Baroni GS; Foschi FG; Biasini E; Masotto A; Virdone R; Bernardi M; Trevisani F;
    Liver Int; 2017 Mar; 37(3):423-433. PubMed ID: 27566596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma.
    Peng Z; Chen S; Xiao H; Wang Y; Li J; Mei J; Chen Z; Zhou Q; Feng S; Chen M; Qian G; Peng S; Kuang M
    Radiology; 2019 Jul; 292(1):237-247. PubMed ID: 31135299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of hepatic resection and transarterial chemoembolization for solitary hepatocellular carcinoma.
    Zhang DZ; Wei XD; Wang XP
    World J Gastroenterol; 2015 Apr; 21(15):4635-43. PubMed ID: 25914473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The presence of microvascular invasion guides treatment strategy in recurrent HBV-related HCC.
    Chen SL; Xiao H; Xie ZL; Shen JX; Chen ZB; Wang YQ; Li B; Peng ZW; Kuang M; Lai JM; Peng S
    Eur Radiol; 2020 Jun; 30(6):3473-3485. PubMed ID: 32048035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing the management of patients with BCLC stage-B hepatocellular carcinoma: Modern surgical resection as a feasible alternative to transarterial chemoemolization.
    Ciria R; López-Cillero P; Gallardo AB; Cabrera J; Pleguezuelo M; Ayllón MD; Luque A; Zurera L; Espejo JJ; Rodríguez-Perálvarez M; Montero JL; de la Mata M; Briceño J
    Eur J Surg Oncol; 2015 Sep; 41(9):1153-61. PubMed ID: 26118317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver resection versus transarterial chemoembolization for the initial treatment of Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma.
    Yang B; Zheng B; Yang M; Zeng Z; Yang F; Pu J; Li C; Liao Z
    Hepatol Int; 2018 Sep; 12(5):417-428. PubMed ID: 30073454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system.
    Han K; Kim JH
    World J Gastroenterol; 2015 Sep; 21(36):10327-35. PubMed ID: 26420959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcomes of second treatment after initial transarterial chemoembolization in patients with hepatocellular carcinoma.
    Kim YI; Park JW; Kwak HW; Kim BH; Lee JH; Lee IJ; Kim TH; Kim SH; Koh YH; Kim HB; Kim CM
    Liver Int; 2014 Sep; 34(8):1278-86. PubMed ID: 24649961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Barcelona clinic liver cancer stage B hepatocellular carcinoma: transarterial chemoembolization or hepatic resection?
    Jianyong L; Lunan Y; Wentao W; Yong Z; Bo L; Tianfu W; Minqing X; Jiaying Y
    Medicine (Baltimore); 2014 Nov; 93(26):e180. PubMed ID: 25474433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.